TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02068144

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
Study: NCT00565565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Study: NCT01717703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1% chocolate milk
Study: NCT00576251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3%/Dexamethasone 0.05%
Description: Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
Study: NCT03201861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: weekly paclitaxel and cisplatin
Study: NCT00576251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBRADEX
Description: TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
Study: NCT01814488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic transplant
Description: Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice.
Study: NCT03201861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC to docetaxel or paclitaxel
Description: Standard adjuvant chemotherapy recommended by guideline
Study: NCT02299752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-gloving system
Description: single-gloving system was used during Catheterization
Study: NCT01124448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2
Description: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
Study: NCT02299752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-gloving system
Description: double-gloving system was used during Catheterization. inner and outer gloves were the same size
Study: NCT01124448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS2
Description: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
Study: NCT02193256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Titrated over 1 week to a maximum dose of 2mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Titrated over 1 week to a maximum dose of 2mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Titrated over 3 weeks to a maximum dose of 8mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03284255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: study group
Description: study group in which patient will accept the treatment of Bioresorbable Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
Study: NCT03314714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute bout of endurance exercise
Description: Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
Study: NCT02287701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study: NCT03930641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTH258
Description: 6 mg in prefilled syringe
Study: NCT03849976

Intervention type: BEHAVIORAL
Intervention: Therapeutic communication
Description: Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
Study: NCT05707624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video education
Description: In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the routine procedure
Description: the routine procedure
Study: NCT01897272

Intervention type: BEHAVIORAL
Intervention: Splinting
Description: One group will have their wrist splinted after their carpal tunnel release surgery.
Study: NCT00087880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
Study: NCT03817060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation of embryos at cleavage stage
Description: cryopreservation of embryos at cleavage stage (day 3) of embryo development

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation of embryos at blastocyst stage
Description: cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
Study: NCT03482635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study: NCT02769858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Light therapy glasses
Study: NCT03858868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Church and park-based intervention
Description: Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard health education on physical activity
Description: Participants will receive publicly available brochures, tip sheets, etc. about physical activity
Study: NCT01651546

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intermittent catheterization test
Description: I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
Study: NCT04235452

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potential
Description: Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out.

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potential
Description: Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out.
Study: NCT03421756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
Study: NCT04027374

Intervention type: PROCEDURE
Intervention: Fetal surgery for MMC repair
Description: Fetal surgery for MMC repair
Study: NCT04529330

Intervention type: PROCEDURE
Intervention: fasciotomy
Description: if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS

Intervention type: PROCEDURE
Intervention: fasciotomy
Description: if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
Study: NCT00732420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topoisomerase I inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topoisomerase I inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Tyrosine kinase inhibitor
Study: NCT00444457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnC
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
Study: NCT04508036

Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal of blood samples for D-Dimer
Description: Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal of blood samples for Fibrinogen
Description: Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic Examination
Description: At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
Study: NCT01644136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo standard robotic assisted laparoscopic prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional lymph node dissection
Description: Undergo pelvic lymph node dissection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microsphere-mediated lymphocele prevention
Description: Undergo microsphere-mediated lymphocele prevention
Study: NCT03521648

Intervention type: PROCEDURE
Intervention: PAE
Description: Prostatic artery embolization

Intervention type: PROCEDURE
Intervention: TURP
Description: Transurethral resection of the prostate

Intervention type: PROCEDURE
Intervention: Other
Description: Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
Study: NCT04223778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOR/ISL
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Baseline background ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
Study: NCT01706848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celotres
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Closure by Standard of Care
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
Study: NCT03013244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Body Project: More Than Muscles
Description: Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
Study: NCT01362686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
Study: NCT04816799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Startle Adjuvant Rehabilitation Therapy (START)
Description: Exposure to loud acoustic stimulus during training of motor task (in this case speech).
Study: NCT03811587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking diet
Description: The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
Study: NCT00307931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks.
Study: NCT03244124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Etching Application Strategy
Description: In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study: NCT01362686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
Study: NCT01552187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 48 to 72 hours before surgery till 1 months after surgery
Study: NCT00311558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: SSG x 5 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: SSG \& IFN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSG & interferon
Description: 1 arm study with SSG \& interferon
Study: NCT02117596

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: 1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
Study: NCT00063583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
Study: NCT01357304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment and PAR
Description: Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
Study: NCT03226132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia
Description: Brief Behavioral Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Contact
Description: Repeated Contact
Study: NCT01969799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin fosfomycin inhalation solution
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized placebo
Description: Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System